



Supplementary Figure 1. Quantile-quantile plot for the 7.1 million chi-square statistics with high-info content from the meta-analysis. The read diagonal line represents expected distribution assuming no inflation of the chi-square statistics.




b

а




Supplementary Figure 2.




d

С




Supplementary Figure 2. Cont.

3




f

е




Supplementary Figure 2. Cont.


4



Supplementary Figure 2. Cont. Regional association plot for variants with imputation information score ≥ 0.90 and located at one of the newly discovered thyroid cancer risk loci. Shown are the negative log₁₀-transformed *P*-values from the meta-analysis The risk loci are located on: 1q42.2 (a), 3q26.2 (b), 5p15.33 (c), 5q22.1 (d), 10q24.33 (e), and 15q22.33 (f and g). The lead marker at each locus is represented by a purple circle and other circle-colors indicate linkage disequilibrium (LD) with lead marker (LD is represented as the correlation coefficient (r²) calculated based on the Icelandic whole-genome sequencing dataset. The red line shows the recombination rate from Phase 2 HapMap estimated from phased haplotypes in HapMap Release 22 (Ref.¹) estimated from the CEU, YRI and JPT+CHB populations, and mapped onto NCBI hg38, Build38. The plot was created using a standalone version of the LocusZoom software²




Supplementary Figure 3. Shown is the QTL association effect in standard deviation units (s.d.) for serum levels of thyroid stimulating hormone (the y-axis) and the log of the odds ratio (OR) from the association analysis of thyroid cancer (the x-axis); for previously published^{3,4} thyroid cancer risk variants (filled red circles), located on 2q35, 8p12, 9q22.33 and 14q13.3, as well as for variants reported in current study (filled blue circles), located on 1q42.2, 3q26.2, 5q22.1, 10q24.33, 15q22.33. The error bars for each data-point in the figure denote plus or minus (+/-) one standard error. The broken horizontal line indicates the cero on the y-axis. The data used to generate this figure can be found in Table 2 of the main text, Supplementary Table 2 and Supplementary Table 4.



Supplementary Figure 4. Expression levels of EPB41L4A in a collection of human tissues from the GTEx consortium

Expression values are shown in RPKM (Reads Per Kilobase of transcript per Million mapped reads), calculated from a gene model with isoforms collapsed to a single gene. No other normalization steps have been applied. Box plots are shown as median and 25th and 75th percentiles; points are displayed as outliers if they are above or below 1.5 times the interquartile range indicated by the whiskers. For further details, see the GTEx homepage: (date accessed July 6th, 2016; http://www.gtexportal.org/home/).



Supplementary Figure 5. Expression levels of SMAD3 in a collection of tissues from the GTEx consortium

Expression values are shown in RPKM (Reads Per Kilobase of transcript per Million mapped reads), calculated from a gene model with isoforms collapsed to a single gene. No other normalization steps have been applied. Box plots are shown as median and 25th and 75th percentiles; points are displayed as outliers if they are above or below 1.5 times the interquartile range indicated by the whiskers. For further details, see the GTEx homepage: (date accessed July 6th, 2016; http://www.gtexportal.org/home/).

| | | Pat | ients | | Controls | | | | |
|-----------------|--------------|---|----------------|---------------------|--------------|---|----------------|---------------------|--|
| Study group | Count (n) | Average age at diagnosis (years) | Females (n) | Fraction females | Count (n) | Average age at inclusion (years) | Females (n) | Fraction females | |
| Iceland | 1,003 | 53 | 714 | 71% | 278,991 | 57 | 135,743 | 49% | |
| Houston, USA | 250 | 45 | 173 | 69% | 363 | 53 | 202 | 56% | |
| Columbus, USA | 1,580 | 43 | 1,175 | 74% | 1,628 | 45 | 1,204 | 74% | |
| The Netherlands | 85 | 40 | 60 | 71% | 4,956 | 55 | 2,725 | 55% | |
| Spain | 83 | 49 | 65 | 78% | 1,612 | 47 | 822 | 51% | |
| Total | 3,001 | | | | 287,550 | | | | |

Supplementary Table 1. Information about samples included in GWAS and meta-analysis for each study group.

| Locus | Marker ^a | Position (bp) | OA | EA | EAF | Study group | Allelic OR (95% CI) | Р |
|---------|--------------------------------|---------------|----|----|-------|-----------------|---------------------|---------|
| 2q35 | rs11693806 | 217,427,435 | G | С | 0.285 | Iceland | 1.49 (1.35, 1.64) | 3.6E-14 |
| | $P_{het} = 0.0069; I^2 = 71.7$ | | | | 0.318 | Columbus, USA | 1.28 (1.15, 1.43) | 1.0E-05 |
| | | | | | 0.484 | Houston, USA | 1.92 (1.52, 2.44) | 6.7E-08 |
| | | | | | 0.266 | The Netherlands | 1.82 (1.30, 2.56) | 5.8E-04 |
| | | | | | 0.242 | Spain | 1.19 (0.83, 1.69) | 0.35 |
| | | | | | 0.319 | All combined | 1.43 (1.33, 1.54) | 1.5E-24 |
| 2q35 | rs966423 | 217,445,617 | Т | С | 0.443 | Iceland | 1.32 (1.19, 1.45) | 3.2E-08 |
| | $P_{het} = 0.057; I^2 = 56.3$ | | | | 0.453 | Columbus, USA | 1.19 (1.09, 1.32) | 4.2E-04 |
| | | | | | 0.341 | Houston, USA | 1.52 (1.22, 1.89) | 2.7E-04 |
| | | | | | 0.404 | The Netherlands | 1.75 (1.28, 2.38) | 3.6E-04 |
| | | | | | 0.407 | Spain | 1.11 (0.81, 1.52) | 0.52 |
| | | | | | 0.41 | All combined | 1.28 (1.20, 1.37) | 8.3E-15 |
| 8p12 | rs2466076 | 32,575,278 | Т | G | 0.467 | Iceland | 1.33 (1.20, 1.47) | 6.1E-09 |
| | $P_{het} = 0.41; I^2 = 0$ | | | | 0.528 | Columbus, USA | 1.27 (1.15, 1.41) | 2.5E-06 |
| | | | | | 0.542 | Houston, USA | 1.47 (1.16, 1.89) | 0.0017 |
| | | | | | 0.464 | The Netherlands | 1.64 (1.20, 2.22) | 0.0015 |
| | | | | | 0.421 | Spain | 1.15 (0.84, 1.59) | 0.38 |
| | | | | | 0.484 | All combined | 1.32 (1.23, 1.41) | 1.5E-17 |
| 8p12 | rs2439302 | 32,574,851 | С | G | 0.458 | Iceland | 1.33 (1.20, 1.47) | 6.2E-09 |
| 1 | $P_{het} = 0.71; I^2 = 0$ | , , | | | 0.525 | Columbus, USA | 1.27 (1.14, 1.39) | 5.0E-06 |
| | , | | | | 0.531 | Houston, USA | 1.39 (1.10, 1.79) | 0.0065 |
| | | | | | 0.465 | The Netherlands | 1.56 (1.15, 2.13) | 0.0048 |
| | | | | | 0.416 | Spain | 1.28 (0.93, 1.75) | 0.13 |
| | | | | | 0.479 | All combined | 1.32 (1.23, 1.41) | 5.7E-17 |
| 9q22.33 | rs1588635 | 97,775,520 | С | А | 0.356 | Iceland | 1.61 (1.47, 1.79) | 1.5E-21 |
| | $P_{het} = 0.48; I^2 = 0$ | | | | 0.476 | Columbus, USA | 1.82 (1.64, 2.00) | 8.0E-32 |
| | | | | | 0.463 | Houston, USA | 1.72 (1.35, 2.17) | 8.3E-06 |
| | | | | | 0.334 | The Netherlands | 1.47 (1.06, 2.00) | 0.021 |
| | | | | | 0.352 | Spain | 1.67 (1.20, 2.33) | 0.0024 |
| | | | | | 0.396 | All combined | 1.70 (1.59, 1.82) | 2.0E-58 |
| 9q22.33 | rs965513 | 97,793,827 | G | А | 0.355 | Iceland | 1.61 (1.45, 1.75) | 4.0E-21 |
| | $P_{het} = 0.52; I^2 = 0$ | | | | 0.475 | Columbus, USA | 1.79 (1.61, 1.96) | 6.7E-31 |
| | | | | | 0.468 | Houston, USA | 1.75 (1.39, 2.22) | 3.7E-06 |
| | | | | | 0.333 | The Netherlands | 1.47 (1.06, 2.00) | 0.020 |
| | | | | | 0.355 | Spain | 1.64 (1.18, 2.27) | 0.0031 |
| | | | | | 0.397 | All combined | 1.70 (1.59, 1.79) | 2.2E-57 |

| Supplemen | tary Table 2 cont. | | | | | | | |
|-----------|-------------------------------|---------------|----|----|--------|-----------------|---------------------|---------|
| Locus | Marker ^a | Position (bp) | OA | EA | EAF | Study group | Allelic OR (95% CI) | Р |
| 14q13.3 | rs368187 | 36,063,370 | С | G | 0.523 | Iceland | 1.49 (1.35, 1.64) | 7.2E-15 |
| | $P_{het} = 0.089; I^2 = 50.5$ | | | | 0.626 | Columbus, USA | 1.35 (1.22, 1.49) | 3.0E-09 |
| | | | | | 0.615 | Houston, USA | 1.28 (1.00, 1.64) | 0.051 |
| | | | | | 0.583 | The Netherlands | 1.47 (1.08, 2.00) | 0.014 |
| | | | | | 0.557 | Spain | 0.95 (0.69, 1.30) | 0.74 |
| | | | | | 0.581 | All combined | 1.39 (1.30, 1.47) | 5.1E-23 |
| 14q13.3 | rs944289 | 36,180,040 | С | Т | 0.561 | Iceland | 1.49 (1.35, 1.65) | 1.0E-14 |
| - | $P_{het} = 0.031; I^2 = 62.4$ | | | | 0.642 | Columbus, USA | 1.28 (1.15, 1.41) | 2.1E-06 |
| | | | | | 0.624 | Houston, USA | 1.17 (0.91, 1.50) | 0.23 |
| | | | | | 0.614 | The Netherlands | 1.57 (1.15, 2.14) | 0.0049 |
| | | | | | 0.576 | Spain | 0.99 (0.72, 1.36) | 0.96 |
| | | | | | 0.603 | All combined | 1.35 (1.27, 1.44) | 2.1E-19 |
| 14q13.3 | rs116909374 | 36,269,155 | С | Т | 0.0492 | Iceland | 1.70 (1.41, 2.06) | 4.2E-08 |
| | $P_{het} = 0.85; I^2 = 0$ | | | | 0.0445 | Columbus, USA | 1.67 (1.24, 2.24) | 7.4E-04 |
| | | | | | 0.0500 | Houston, USA | 2.51 (1.19, 5.31) | 0.016 |
| | | | | | 0.0352 | The Netherlands | 1.30 (0.50, 3.42) | 0.59 |
| | | | | | 0.0272 | Spain | 1.87 (0.57, 6.20) | 0.30 |
| | | | | | 0.0412 | All combined | 1.71 (1.47, 2.00) | 6.2E-12 |

Position is according to Build 38 of the reference genome. Effect allele (EA), other allele (OA), effect allele frequency in controls (EAF), odds ratio (OR) for effect allele with upper and lower 95% confidence intervals (CI).

^aFor all markers but rs116909374, was the imputation information score ≥ 0.97 and the association results shown are imputed results from the metaanalysis of the Icelandic, US (Columbus, Ohio and Houston, Texas), Dutch and Spanish study groups. For rs116909374 the combined results are made up of imputed data from Iceland (with imputation information score = 1.0) and directly generated genotypes for the other four study groups. The pairwise correlation between marker at each locus is as follows (the marker listed latter is the previously published^{3,4} one):

At 2q35 the r^2 is 0.47 between rs11693806 and rs966423.

At 8p12 the r^2 is 0.94 rs2466076 and rs2439302.

At 9q22.33 the r^2 is 0.99 between rs1588635 and rs965513.

At 14q13.3 (for the more common markers) the r² is 0.70 between rs368187 and rs944289.

At 14q13.3 (for the less common marker) the most significant marker in the current study is the same as previously reported (rs116909374).

| i) Conditional analysis results for 2q35 | | | | | | | | | |
|--|---------------------------------|----------------|--|---------|--|--|--|--|--|
| | Unadjusted result rs966423_C | ts for | Results for rs966423_C adjusted on rs11693806 | | | | | | |
| Study group | Allelic OR (95% CI) | P-value | Allelic OR (95% CI) | P-value | | | | | |
| Iceland | 1.32 (1.19, 1.45) | 3.2E-08 | 0.96 (0.83, 1.12) | 0.62 | | | | | |
| Columbus, USA | 1.19 (1.09, 1.32) | 4.2E-04 | 1.04 (0.90, 1.20) | 0.56 | | | | | |
| Houston, USA | 1.52 (1.22, 1.89) | 2.7E-04 | 1.37 (0.56, 3.39) | 0.49 | | | | | |
| The Netherlands | 1.75 (1.28, 2.38) | 3.6E-04 | 1.51 (0.95, 2.40) | 0.082 | | | | | |
| Spain | 1.11 (0.81, 1.52) | 0.52 | 1.01 (0.66, 1.54) | 0.96 | | | | | |
| All combined | 1.28 (1.20, 1.37) | 8.3E-15 | 1.03 (0.93, 1.13) | 0.61 | | | | | |

Supplementary Table 3. Conditional analysis of the 2q35 and 5p15.33 loci

| | Unadjusted resul rs11693806_(| | Results for rs11693806_C adjusted on rs966423 | | | | |
|-----------------|----------------------------------|---------|--|---------|--|--|--|
| Study group | Allelic OR (95% CI) | P-value | Allelic OR (95% CI) | P-value | | | |
| Iceland | 1.49 (1.35, 1.64) | 3.6E-14 | 1.41 (1.22, 1.63) | 2.6E-06 | | | |
| Columbus, USA | 1.28 (1.15, 1.43) | 1.0E-05 | 1.24 (1.06, 1.44) | 0.0066 | | | |
| Houston, USA | 1.92 (1.52, 2.44) | 6.7E-08 | 0.73 (0.28, 1.90) | 0.52 | | | |
| The Netherlands | 1.82 (1.30, 2.56) | 5.8E-04 | 1.29 (0.84, 1.98) | 0.24 | | | |
| Spain | 1.19 (0.83, 1.69) | 0.35 | 1.17 (0.74, 1.84) | 0.50 | | | |
| All combined | 1.43 (1.33, 1.54) | 1.5E-24 | 1.31 (1.19, 1.44) | 9.5E-08 | | | |

ii) Conditional analysis results for 5p15.33

| | Unadjusted result rs2736100_C | | Results for rs2736100_C adjusted on rs10069690 |
|-----------------|----------------------------------|----------------|---|
| Study group | Allelic OR (95% CI) | P-value | Allelic OR (95% CI) P-value |
| Iceland | 1.15 (1.04, 1.27) | 6.5E-03 | 1.05 (0.94, 1.17) 0.36 |
| Columbus, USA | 1.12 (1.01, 1.23) | 0.025 | 1.09 (0.97, 1.22) 0.15 |
| Houston, USA | 0.93 (0.74, 1.16) | 0.49 | 1.16 (0.51, 2.67) 0.72 |
| The Netherlands | 1.25 (0.93, 1.69) | 0.14 | 1.15 (0.81, 1.63) 0.44 |
| Spain | 1.04 (0.76, 1.43) | 0.82 | 0.84 (0.57, 1.23) 0.36 |
| All combined | 1.11 (1.04, 1.19) | 7.3E-04 | 1.06 (0.99, 1.15) 0.11 |

| | Unadjusted result rs10069690_7 | | Results for rs10069690_T adjusted on rs2736100 | | | | |
|-----------------|-----------------------------------|---------|---|---------|--|--|--|
| Study group | Allelic OR (95% CI) | P-value | Allelic OR (95% CI) | P-value | | | |
| Iceland | 1.25 (1.12, 1.40) | 4.8E-05 | 1.23 (1.09, 1.39) | 6.7E-04 | | | |
| Columbus, USA | 1.12 (1.00, 1.25) | 0.043 | 1.07 (0.94, 1.22) | 0.28 | | | |
| Houston, USA | 1.21 (0.94, 1.57) | 0.14 | 1.91 (0.65, 5.58) | 0.24 | | | |
| The Netherlands | 1.38 (0.97, 1.96) | 0.074 | 1.26 (0.86, 1.85) | 0.23 | | | |
| Spain | 1.40 (0.99, 1.98) | 0.059 | 1.53 (1.02, 2.30) | 0.039 | | | |
| All combined | 1.20 (1.12, 1.29) | 3.2E-07 | 1.18 (1.08, 1.28) | 1.3E-04 | | | |

Shown are association results from the meta-analysis before and after conditional analysis, the allelic odd ratio (OR) with 95% confidence intervals and the P-value. The correlation (r^2) in Iceland between rs966423 and rs11693806 is 0.47; and between rs10069690 and rs2736100 is 0.19.

| | | | | TSH | | fT3 | | fT4 | |
|----------|----------------|-----|---------------|---------------|-------|---------------|------|---------------|-------|
| Locus | Marker (EA) | Chr | Position (bp) | Effect (s.d.) | Р | Effect (s.d.) | Р | Effect (s.d.) | Р |
| 1q42.2 | rs12129938 (A) | 1 | 233,276,815 | 0.000 | 0.96 | 0.004 | 0.54 | -0.003 | 0.59 |
| 3q26.2 | rs6793295 (T) | 3 | 169,800,667 | -0.006 | 0.20 | 0.000 | 0.96 | -0.007 | 0.11 |
| 5p15.33 | rs10069690 (T) | 5 | 1,279,675 | 0.004 | 0.38 | 0.009 | 0.16 | 0.007 | 0.13 |
| 5q22.1 | rs73227498 (A) | 5 | 112,150,207 | -0.010 | 0.054 | 0.000 | 0.95 | 0.014 | 0.010 |
| 10q24.33 | rs7902587 (T) | 10 | 103,934,543 | 0.001 | 0.90 | 0.007 | 0.44 | 0.006 | 0.34 |
| 15q22.33 | rs56062135 (T) | 15 | 67,163,292 | -0.006 | 0.18 | -0.003 | 0.63 | 0.001 | 0.90 |
| 15q22.33 | rs2289261 (C) | 15 | 67,165,147 | -0.002 | 0.63 | 0.000 | 0.93 | 0.006 | 0.12 |

Supplementary Table 4. Association results for thyroid cancer risk variants and serum levels of thyroid related hormones.

a) Results for the six risk loci reported in the current study

b) Results for strongest variants in the current study at the five previously reported^{3,4} thyroid cancer risk loci

| | | | | TSH | | fT3 | | fT4 | |
|---------|-----------------|-----|---------------|---------------|----------|---------------|---------|---------------|---------|
| Locus | Marker (EA) | Chr | Position (bp) | Effect (s.d.) | Р | Effect (s.d.) | Р | Effect (s.d.) | Р |
| 2q35 | rs11693806 (C) | 2 | 217,427,435 | -0.021 | 4.6E-07 | -0.005 | 0.35 | 0.019 | 1.8E-05 |
| 8p12 | rs2466076 (G) | 8 | 32,575,278 | -0.037 | 2.1E-23 | 0.003 | 0.55 | 0.011 | 0.0047 |
| 9q22.33 | rs1588635 (A) | 9 | 97,775,520 | -0.087 | 2.5E-113 | 0.038 | 2.2E-12 | -0.049 | 2.4E-33 |
| 14q13.3 | rs368187 (G) | 14 | 36,063,370 | -0.023 | 3.7E-10 | 0.006 | 0.26 | 0.012 | 0.0015 |
| 14q13.3 | rs116909374 (T) | 14 | 36,269,155 | -0.139 | 1.2E-59 | 0.014 | 0.23 | 0.061 | 1.5E-11 |

Quantitative trait locus (QTL) association results are for the effect-allele (EA) of all markers. Shown are: the chromosome (Chr), the position in base pairs (bp) in Build 38, the P-value (P), and the effect size for serum levels of: thyroid stimulating hormone (TSH), free-triiodothyronine (fT3), and free-thyroxine (fT4). The effect size is measured in standard-deviation units (s.d.). The minus (-) sign in front of the effect size stands for a decreasing effect whereas no sign stands for an increasing effect. The QTL association results are based on measurements for the following number of Icelanders: TSH = 188,057 individuals; fT3 = 51,047 individuals; fT4 = 120,879 individuals.

References

- 1. International HapMap, C. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851-61 (2007).
- Pruim, R.J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 26, 2336-7 (2010).
- 3. Gudmundsson, J. *et al.* Discovery of common variants associated with low TSH levels and thyroid cancer risk. *Nat Genet* **44**, 319-22 (2012).
- 4. Gudmundsson, J. *et al.* Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. *Nat Genet* **41**, 460-4 (2009).